The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2–0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0–1.7) and fatigue (OR 1.3; 95% CI 1.0–1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.

Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey / Naveen, R.; Thakare, D. R.; Kuwana, M.; Pauling, J. D.; Day, J.; Joshi, M.; Parodis, I.; Sen, P.; Jagtap, K.; Nikiphorou, E.; Saha, S.; Agarwal, V.; Chatterjee, T.; Lilleker, J. B.; Kardes, S.; Milchert, M.; Gheita, T.; Salim, B.; Velikova, T.; Gracia-Ramos, A. E.; Tan, A. L.; Nune, A.; Cavagna, L.; Saavedra, M. A.; Shinjo, S. K.; Ziade, N.; Knitza, J.; Distler, O.; Chinoy, H.; Barman, B.; Singh, Y. P.; Ranjan, R.; Jain, A.; Pandya, S. C.; Pilania, R. K.; Sharma, A.; Manesh Manoj, M.; Gupta, V.; Kavadichanda, C. G.; Patro, P. S.; Ajmani, S.; Phatak, S.; Goswami, R. P.; Chowdhury, A. C.; Mathew, A. J.; Shenoy, P.; Asranna, A.; Bommakanti, K. T.; Shukla, A.; Pande, A. R.; Chandwar, K.; Cansu, D. U.; Pauling, J. D.; Wincup, C.; Makol, A.; Del Papa, N.; Sambataro, G.; Fabiola, A.; Govoni, M.; Parisi, S.; Bocci, E. B.; Sebastiani, G. D.; Fusaro, E.; Sebastiani, M.; Quartuccio, L.; Franceschini, F.; Sainaghi, P. P.; Orsolini, G.; De Angelis, R.; Danielli, M. G.; Venerito, V.; Traboco, L. S.; Wibowo, S. A. K.; Serrano, J. R.; La Torre, I. G. -D.; Tehozol, E. A. Z.; Loarce-Martos, J.; Prieto-Gonzalez, S.; Gonzalez, R. A.; Yoshida, A.; Nakashima, R.; Sato, S.; Kimura, N.; Kaneko, Y.; Tomaras, S.; Gromova, M. A.; Aharonov, O.; Hmamouchi, I.; Hoff, L. S.; Giannini, M.; Maurier, F.; Campagne, J.; Meyer, A.; Nagy-Vincze, M.; Langguth, D.; Limaye, V.; Needham, M.; Srivastav, N.; Hudson, M.; Landon-Cardinal, O.; Shaharir, S. S.; Zuleta, W. G. R.; Silva, J. A. P.; Fonseca, J. E.; Zimba, O.; Aggarwal, R.; Gupta, L.; Agarwal, V.; Makol, A.. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 1437-160X. - 43:7(2023), pp. 1265-1275. [10.1007/s00296-023-05310-9]

Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey

Sebastiani M.;
2023

Abstract

The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2–0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0–1.7) and fatigue (OR 1.3; 95% CI 1.0–1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.
2023
43
7
1265
1275
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey / Naveen, R.; Thakare, D. R.; Kuwana, M.; Pauling, J. D.; Day, J.; Joshi, M.; Parodis, I.; Sen, P.; Jagtap, K.; Nikiphorou, E.; Saha, S.; Agarwal, V.; Chatterjee, T.; Lilleker, J. B.; Kardes, S.; Milchert, M.; Gheita, T.; Salim, B.; Velikova, T.; Gracia-Ramos, A. E.; Tan, A. L.; Nune, A.; Cavagna, L.; Saavedra, M. A.; Shinjo, S. K.; Ziade, N.; Knitza, J.; Distler, O.; Chinoy, H.; Barman, B.; Singh, Y. P.; Ranjan, R.; Jain, A.; Pandya, S. C.; Pilania, R. K.; Sharma, A.; Manesh Manoj, M.; Gupta, V.; Kavadichanda, C. G.; Patro, P. S.; Ajmani, S.; Phatak, S.; Goswami, R. P.; Chowdhury, A. C.; Mathew, A. J.; Shenoy, P.; Asranna, A.; Bommakanti, K. T.; Shukla, A.; Pande, A. R.; Chandwar, K.; Cansu, D. U.; Pauling, J. D.; Wincup, C.; Makol, A.; Del Papa, N.; Sambataro, G.; Fabiola, A.; Govoni, M.; Parisi, S.; Bocci, E. B.; Sebastiani, G. D.; Fusaro, E.; Sebastiani, M.; Quartuccio, L.; Franceschini, F.; Sainaghi, P. P.; Orsolini, G.; De Angelis, R.; Danielli, M. G.; Venerito, V.; Traboco, L. S.; Wibowo, S. A. K.; Serrano, J. R.; La Torre, I. G. -D.; Tehozol, E. A. Z.; Loarce-Martos, J.; Prieto-Gonzalez, S.; Gonzalez, R. A.; Yoshida, A.; Nakashima, R.; Sato, S.; Kimura, N.; Kaneko, Y.; Tomaras, S.; Gromova, M. A.; Aharonov, O.; Hmamouchi, I.; Hoff, L. S.; Giannini, M.; Maurier, F.; Campagne, J.; Meyer, A.; Nagy-Vincze, M.; Langguth, D.; Limaye, V.; Needham, M.; Srivastav, N.; Hudson, M.; Landon-Cardinal, O.; Shaharir, S. S.; Zuleta, W. G. R.; Silva, J. A. P.; Fonseca, J. E.; Zimba, O.; Aggarwal, R.; Gupta, L.; Agarwal, V.; Makol, A.. - In: RHEUMATOLOGY INTERNATIONAL. - ISSN 1437-160X. - 43:7(2023), pp. 1265-1275. [10.1007/s00296-023-05310-9]
Naveen, R.; Thakare, D. R.; Kuwana, M.; Pauling, J. D.; Day, J.; Joshi, M.; Parodis, I.; Sen, P.; Jagtap, K.; Nikiphorou, E.; Saha, S.; Agarwal, V.; C...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1305487
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact